173999-17-2

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-5-(methoxymethyl)pyridine is used as a building block for the synthesis of various bioactive compounds, contributing to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
3-Bromo-5-(methoxymethyl)pyridine is utilized as a key intermediate in the production of agrochemicals, such as pesticides and herbicides, to enhance crop protection and yield.
Used as a Reagent in Chemical Reactions:
Due to its ability to undergo functional group transformations, 3-bromo-5-(methoxymethyl)pyridine is employed as a reagent in various chemical reactions, facilitating the synthesis of a wide range of important compounds.

Upstream product

• 37669-64-0 (5-bromopyridin-3-yl)methanol 
• 74-88-4 methyl iodide 
• 29681-44-5 5-bromo-3-pyridine carboxylic acid methyl ester 
• 113118-81-3 5-bromopyridine-3-carbaldehyde 

Relevant academic research and scientific papers

[3H]-methoxymethyl-MTEP and [3H]-methoxy-PEPy: Potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor

The design, synthesis, and characterization of two potent, non-competitive radioligands, [3H]-methoxymethyl-MTEP and [3H]-methoxy-PEPy, that are selective for the mGlu5 receptor are described.

1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS

The present invention relates to the 1 H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta (GSK-3β) inhibitors and to their use in the treatment of GSK-3β-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) osteoporosis, (viii) cardiac hypertrophy, (ix) epilepsies and (x) neuropathic pain.

NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF

An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. Th e present invention provides a nicotinamide derivative represented by the follo wing formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl g roup, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each opti onally having at least one substituent; R 3 represents an aryl group or a hetero cyclic group each optionally having at least one substituent; and R 4 and R 5 e ach independently represent a hydrogen atom; and R 2 and R 4 may form a cyc lic amino group optionally having at least one substituent together with the ni trogen atom to which they bind) or a salt thereof, and a pharmaceutical comp osition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds

Patients susceptible to or suffering from central nervous system disorders (e.g., Alzheimer's disease, Parkinson's disease, Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl subst